• ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy

    Source: Nasdaq GlobeNewswire / 16 May 2024 15:35:00   America/Chicago

    SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) --

    When:          May 17–22, 2024
    Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101
                           Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101

    Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:

    • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV)
      in Opioid Users – a European Registry
      • Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-B
      • Presented by Jean-Louis Pepin, MD, Grenoble Alpes University, France
    • An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States into 2050
      • Monday, May 20, 9:15 a.m. - 4:15 p.m., SDCC Area C Hall A-B2
      • Presented by Elroy Boers, PhD, ResMed Science Center
    • All-Cause Mortality in Obstructive Sleep Apnea
      • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B
      • Presented by Atul Malhotra, MD, University of California, San Diego
    • Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare Database
      • Monday, May 20, 2:15 p.m. - 4:15 p.m., SDCC 32A-B
      • Presented by Holger Woehrle, MD, Ulm Lung Centre, Germany
    • Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation – Outcomes in Patients with Treatment-Emergent or Persistent Central Sleep Apnea
      • Tuesday, May 21, 2:15 p.m. - 4:15 p.m., Marriott Marquis Pacific Ballroom 15-17
      • Presented by Michael Arzt, MD, Universitätsklinikum Regensburg, Germany

    Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient Centricity

    • Monday, May 20, 1:15 - 1:35 p.m., SDCC Innovation Hub 4
    • Presented by Monica Mallampalli, Chief Executive Officer at Alliance of Sleep Apnea Partners, and Carlos Nunez, ResMed Chief Medical Officer

    Booth #1442:            Featuring ResMed’s latest innovations in respiratory care:

    • AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
    • AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask

    Complete list of ResMed sponsored studies to be presented at ATS 2024:

    Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) in opioid users – a European registrySunday, May 19, 2024
    9:15 AM -11:15 AM
    8-year Trends in Obesity, Type 2 Diabetes, and Glucagon-like Peptide-1 (GLP-1) Use in Patients With Obstructive Sleep ApneaSunday May 19, 2024
    9:15 AM - 11:15 AM
    Impact of CPAP Termination on Permanent Work Disability in Obstructive Sleep Apnea: A French Nationwide Alaska Database AnalysisSunday May 19, 2024
    9:15 AM - 4:15 PM
    Tailoring Social Support to Improve PAP Therapy Usage in Obstructive Sleep ApneaSunday May 19, 2024
    9:15 AM - 4:15 PM
    Examining Alignment of Patient Medication-taking Behaviors With Inhaler Usage Recommendations in Chronic Obstructive Pulmonary Disease and AsthmaSunday May 19, 2024
    9:15 AM - 4:15 PM
    Using Natural Language Processing for Qualitative Research: Insights From a Real-world AnalysisSunday May 19, 2024
    9:15 AM - 4:15 PM
    A Qualitative Analysis of Perceptions and Awareness of Air Pollution and Its Health Effects in Asthma Among Asthma-care Professionals Across Southern CaliforniaMonday May 20, 2024
    9:15 AM - 4:15 PM
    An Estimate of the Prevalence of Obstructive Sleep Apnea in the United States Into 2050Monday May 20, 2024
    9:15 AM - 4:15 PM
    All-cause Mortality in Obstructive Sleep Apnea: Systematic Literature Review Including Randomised Trials and Confounding Adjusted Non-randomised Controlled Studies and Meta-analysis of Positive Airway Pressure TreatmentMonday May 20, 2024
    2:15 PM - 4:15 PM
    Impact of Positive Airway Pressure (PAP) Therapy on Hospitalization in Obstructive Sleep Apnea (OSA): Analysis of a German Healthcare DatabaseMonday May 20, 2024
    2:15 PM - 4:15 PM
    Hypoxic Burden but Not AHI Predicts Risk of Cardiovascular Events: A Secondary Analysis of the RICCADSA Clinical TrialMonday May 20, 2024
    2:15 PM - 4:15 PM
    A Digital Quality Improvement Program Delivered By Clinical Pharmacists Can Reduce Acute Care Visits In COPDMonday May 20, 2024
    2:15 PM - 4:15 PM
    Hands-on Simulation Training With Home Ventilators Improves PCCM Fellow Understanding of Nocturnal NIV in Chronic HypercapniaMonday May 20, 2024
    2:15 PM - 4:15 PM
    The Economic and Health Burden of COPD in North America Through 2050: A Scenario Analysis Based on Two Large Data SourcesTuesday May 21, 2024
    9:15 AM - 11:15 AM
    Impact of long-term domiciliary noninvasive ventilation (NIV) on severe exacerbations and survival in Patients with Chronic Obstructive Pulmonary Disease (COPD): a nationwide cohort study using multistate modelsTuesday May 21, 2024
    9:15 AM - 11:15 AM
    Nocturnal Hypoxemic Burden and Micro- and Macrovascular Disease in Patients With Type 2 DiabetesTuesday May 21, 2024
    9:15 AM - 11:15 AM
    Risk Factors for Severe Exacerbation Occurrence Among Patients With COPD-OSA Overlap Syndrome Using Bilevel Positive Airway Pressure TherapyTuesday May 21, 2024
    9:15 AM - 4:15 PM
    Adherence to Glucagon-like Peptide-1 Receptor Agonists (GLP-1s) in Obstructive Sleep Apnea Patients With and Without Type 2 DiabetesTuesday May 21, 2024
    2:15 PM - 4:15 PM
    Treatment of sleep-disordered breathing with adaptive servo-ventilation (READ-ASV) – outcomes in patients with treatment-emergent or persistent central sleep apnea (TE-CSA) in a European registryTuesday, May 21, 2024
    2:15 PM – 4:15 PM
    A Scenario-based Modeling Study to Project the Future Burden of COPD in the United States Accounting for the Effects of E-cigarettesTuesday May 21, 2024
    2:15 PM - 4:15 PM
    The Impact Of Weight Change On Positive Airway Pressure Use In Patients With Obstructive Sleep Apnea And ObesityTuesday May 21, 2024
    2:15 PM - 4:15 PM
    Real World GLP-1 Adherence in Patients with Treated Obstructive Sleep ApneaTuesday May 21, 2024
    2:15 PM - 4:15 PM
    Less REM Sleep Predicts Mortality in Adults With Coronary Artery Disease and Obstructive Sleep Apnea: The RICCADSA TrialTuesday May 21, 2024
    2:15 PM - 4:15 PM
    Gender Specific Differences in a National Sample of Individuals with Comorbid Insomnia, Obstructive Sleep Apnea (OSA), and DepressionWednesday May 22, 2024
    8:15 AM - 10:15 AM
    Use of Weight Management Regimens Among Positive Airway Pressure-Treated Patients With Obstructive Sleep Apnea and ObesityWednesday May 22, 2024
    11:00 AM - 1:00 PM
    A Mixed-methods Exploration of Patient Perspectives on Pap Therapy Initiation: Implications for Improved Outreach and EducationWednesday May 22, 2024
    11:00 AM - 1:00 PM



    Media questions/requests:        
Peter Duckler, +1 (773) 343-3069, pduckler@realchemistry.com
Rowena Kelley, +1 (858) 289-7272, rowena.kelley@resmed.com

    Primary Logo

Share on,